Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03487276 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa (HS)

Interventions

DRUG: IFX-1
DRUG: Placebo

Sponsor

InflaRx GmbH

Collaborators

[object Object]